First Choice Neurology Press Releases

The FDA cleared Fujirebio's Lumipulse Plasma Ratio blood test for the early detection of amyloid plaques associated with Alzheimer's disease (AD). Lumipulse is the first in-vitro diagnostic (IVD) test used in the diagnosis of AD.

First Choice Neurology is proud to announce a groundbreaking partnership with NeuroDiscovery AI (NDAI), a national leader in artificial intelligence, data analytics, and clinical dashboarding for neurology.

Neurologists working in a hospital-integrated setting experience an average income reduction of $9,652

Dementia Specialist, Dr. Jeffrey Gelblum, Expands the Infusion Center in his Jupiter Neurology Office.

Dr. Jeff Gelblum, Neurologist at First Choice Neurology, has brought together clinical, imaging, and laboratory capabilities to provide rapid diagnosis and treatment to individuals suffering from Alzheimer's disease.

First Choice Neurology, the largest neurology group in the United States, is set to make medical history next week as Dr. Jennifer Buczyner and Dr.

Visit First Choice Neurology at the AAN Annual Meeting, Booth 1643 on April 13-18 to learn about physician opportunities.

First Choice Neurology, the largest neurology group in the US, announced that it has been recognized by Modern Healthcare as one of the Top Innovators for 2023.

Dr. Jeffrey Gelblum, Senior Neurologist at First Choice Neurology educates patients about the risk of dementia and Alzheimer's disease.